Sofia Heigis News Today

DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, ...

Oncopeptalks on the companys rights issue March 13, 2024 Listen to Sofia Heigis, CEO, and Henrik Bergentoft, CFO, talk about why Oncopeptides is carrying out a...

Oncopeptides announces successful price negotiations for Pepaxti in GermanyStockholm – September 26, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Ass...

Oncopeptides announces successful price negotiations for Pepaxti in Germany Stockholm - September 26, 2023 - Oncopeptides AB , a biotech company focused on difficult-to-treat...

Oncopeptides launches Oncopeptalks with a fireside chat featuring CEO Sofia Heigis September 20, 2023 Join David Augustsson, Director, Corporate Affairs at...

September 20, 2023 On Tuesday, Sofia Heigis presented Oncopeptides at Aktiedagen in Stockholm, an event organized by Aktiespararna. During...

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma News provided by Share this article STOCKHOLM, March 8, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO ), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that it strengthens the leadership of the European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon a...